AbbVie Inc (ABBV)

ABBV (NYSE:Drugs) EQUITY
$64.90
pos +0.45
+0.70%
Today's Range: 64.32 - 65.12 | ABBV Avg Daily Volume: 9,207,800
Last Update: 07/27/16 - 4:00 PM EDT
Volume: 6,216,627
YTD Performance: 8.79%
Open: $64.32
Previous Close: $64.45
52 Week Range: $45.45 - $71.51
Oustanding Shares: 1,617,358,607
Market Cap: 104,028,505,602
6-Month Chart
TheStreet Ratings Grade for ABBV
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 7 8 8
Moderate Buy 0 0 1 1
Hold 6 6 3 3
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 2.23 2.14 1.81 1.81
Latest Dividend: 0.57
Latest Dividend Yield: 3.54%
Dividend Ex-Date: 07/13/16
Price Earnings Ratio: 19.32
Price Earnings Comparisons:
ABBV Sector Avg. S&P 500
19.32 19.30 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
5.78% -5.33% 43.89%
GROWTH 12 Mo 3 Yr CAGR
Revenue 14.50 0.20 0.07
Net Income 190.00 0.00 -0.01
EPS 185.20 -0.10 -0.02
Earnings for ABBV:
EBITDA 8.37B
Revenue 22.86B
Average Earnings Estimates
Qtr (06/16) Qtr (09/16) FY (12/16) FY (12/17)
Average Estimate $1.20 $1.18 $4.76 $5.66
Number of Analysts 9 6 10 10
High Estimate $1.22 $1.24 $4.80 $5.96
Low Estimate $1.19 $1.14 $4.69 $5.35
Prior Year $1.08 $1.13 $4.29 $4.76
Growth Rate (Year over Year) 11.11% 4.42% 11.03% 18.92%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
It's too cheap for a biotech giant with years of patent protection for its key products and great cash flow.
Valuations are stretched in certain names and industries, so some profit-taking appears in order.
These names are now oversold and are sitting at attractive prices.
Analysts cut valuation estimates after a disappointing drug study. 
With the recent pullback in the stock price, AbbVie is an attractive buy.  
Social media chatter on Wall Street ranged from new forms of so-called 'thematic ETFs' to spiking volatility.
Bearish
Jun 10, 2016 | 7:53 AM EDT
ABBV was downgraded from Outperform to Market Perform, BMO Capital said. $66 price target. Uncertainty is increasing around major growt...
Further near-term weakness to $60 looks like a good spot to go long. Use an appropriate risk level.
This is because they would buy more of the winning stocks lower.
The uptick in the small- and mid-cap space bodes well for future capital appreciation.

Columnist Conversations

Markets in rally mode as Fed once again decides to leave rates unchanged in 9-1 vote.   Some big moves...
UPS will be reporting its 2nd quarter results before Friday's opening bell.  The stock has been fading si...
The FOMC essentially recycled the past couple of of policy statements at the conclusion of its two-day meeting...
we'll roll this to a higher strike, stock is breaking out. SOLD AGN SEP 250 CALL AT 14.40 (in at 9.30) B...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.